Spots Global Cancer Trial Database for Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

Official Title: Clinical Study of Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

Study ID: NCT05871437

Conditions

Early-stage Breast Cancer

Interventions

Huaier granule

Study Description

Brief Summary: This is a prospective, single center, single-arm, phase IV study， to evaluate the effect of Huaier Granule on reducing the level of tumor markers in early-stage breast cancer patients.

Detailed Description: This clinical trial is expected to include 379 patients in the follow-up stage after breast cancer surgery who visited the Breast Surgery Department of Fudan University Shanghai Cancer Hospital from October 2022 to October 2024. Excluding cases where tumor markers (CEA/CA125/CA153) exceed the normal upper limit level in the case of recurrence and metastasis. All participants received treatment with Huaier granules for 1 year, or experienced intolerable toxicity, withdrew from the study for any reason or died, whichever occurred first. The main research indicator is the recovery rate of tumor markers (CEA/CA125/CA153) to normal.